Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Chordoma
- Focus Adverse reactions
- 05 Jun 2024 Planned End Date changed from 1 Nov 2024 to 1 Nov 2026.
- 03 Nov 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 03 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.